Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204966 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2PTPN1MMP2ANPEP | |
| SCHEMBL85511 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2PTPN1MMP2ANPEP | |
| SCHEMBL17644197 | 0.88 | ACE (0.43) | PTPN1MMP2ANPEPGPR119HDAC8 | |
| SCHEMBL875282 | 0.87 | PTPN1 (0.43) | HSD17B10SMN1; SMN2PTPN1MMP2ANPEP | |
| SCHEMBL31080852 | 0.87 | PTPN1 (0.43) | HSD17B10SMN1; SMN2PTPN1MMP2ANPEP | |
| SCHEMBL13804335 | 0.87 | CHRM2 (0.39) | HSD17B10SMN1; SMN2PTPN1MMP2ANPEP | |
| SCHEMBL13059380 | 0.87 | CHRM2 (0.39) | HSD17B10SMN1; SMN2PTPN1MMP2ANPEP | |
| SCHEMBL877760 | 0.87 | PTPN1 (0.43) | HSD17B10SMN1; SMN2PTPN1MMP2ANPEP | |
| SCHEMBL15829069 | 0.87 | CHRM2 (0.39) | HSD17B10SMN1; SMN2PTPN1MMP2ANPEP | |
| SCHEMBL4497625 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2PTPN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110724138-B | Synthesis method of (2S) -4-oxo-2- (3-thiazolidinyl carbonyl) -1-pyrrolidine carboxylic acid tert-butyl ester | 山东邹平大展新材料有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-110724138-A | Synthesis method of (2S) -4-oxo-2- (3-thiazolidinyl carbonyl) -1-pyrrolidine carboxylic acid tert-butyl ester | 山东邹平大展新材料有限公司 | 2020-01-24 | — | — | CN | claimed |
| CN-110372559-A | One kind (4S)-N-Boc-4-- methoxy-L-PROLINE synthetic method | 重庆博腾制药科技股份有限公司 | 2019-10-25 | — | — | CN | claimed |
| CN-106256819-B | One kind (4S)-N-Boc-4- methoxy-L-PROLINE amine salt synthetic method | 重庆博腾制药科技股份有限公司 | 2019-07-09 | — | — | CN | claimed |
| CN-106256819-A | A kind of synthetic method of (4S) N Boc 4 methoxy L proline amine salt | 重庆博腾制药科技股份有限公司 | 2016-12-28 | — | — | CN | claimed |
| CN-105801462-A | Synthesis method of (4S) -N-Boc-4-methoxymethyl-L-proline | 重庆博腾制药科技股份有限公司 | 2016-07-27 | — | — | CN | claimed |
| WO-2026090317-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-5625855-A | Photographic film cassette with lock biasing light shield closed | FUJI PHOTO FILM CO., LTD. (JP) | 1997-04-29 | — | — | US | disclosed |
| EP-0717079-A2 | Injection molded article for photographic photosensitive material, molding method thereof and package using the same | Fuji Photo Film Co., Ltd. (JP) | 1996-06-19 | — | — | EP | disclosed |
| WO-1995004718-A1 | 4-METHYLENEPROLINE DERIVATIVES AS FUNGICIDES | ZENECA LIMITED (GB) | 1995-02-16 | — | — | WO | disclosed |
| US-4983685-A | Using an organic peroxide crosslinker and a detackifier | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4481316-A | 2-MERCAPTOBENZIMIDAZOLE | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1984-11-06 | — | — | US | disclosed |
| US-4393163-A | 2-MERCAPTOBENZIMIDAZOLE OR DERIVATIVE | NITTO CHEMICAL INDUSTRY, CO., LTD. (JP) | 1983-07-12 | — | — | US | disclosed |
| US-4276214-A | CONTAINING AN AMINE ANTIOXIDANT, A BENZIMIDAZOLE OR BENZOTHIAZOLE SULFUR COMPOUND OR ORGANOSULFUR COMPOUND | DAIKIN KOGYO CO., LTD. (JP) | 1981-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | HSD17B10 3996/4885SMN1; SMN2 3692/4885PTPN1 2222/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | HSD17B10 342/4885SMN1; SMN2 36/4885PTPN1 3390/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | HSD17B10 323/4885SMN1; SMN2 37/4885PTPN1 3407/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HSD17B10 687/4885SMN1; SMN2 96/4885PTPN1 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.